Drug Discovery World

AUGUST 1, 2023

Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells that eradicated tumours and prevented their recurrence in mouse models of melanoma. However, these have not been as successful in clinical trials as hoped. The researchers named their approach CATCH.

RNA 52

RNA Bioassay Genome Genomics 52

Drug Discovery World

MAY 10, 2023

This stage is more highly regulated and consists of both preclinical testing and clinical trials. Carcinogenicity testing For decades, the two-year rodent bioassay has been the regulatory standard used to determine the carcinogenic potential of new drugs. In practice, this was typically conducted in rats and mice.

Bioassay 52

Bioassay Genotoxicity Drugs In-Vivo 52

Drug Discovery World

NOVEMBER 30, 2023

Promega had two posters from which to share insight, which included: ‘Cell-based luminescent reporter bioassays for immunotherapies targeting macrophage effector functions’, and ‘Development of bioluminescent no-wash Fc gamma receptor binding immunoassay to guide the development of antibody therapeutics’.

Antibody 59

Antibody Protein Engineer In-Vivo 59